Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Q2 2024 Neurocrine Biosciences Inc Earnings Call Transcript

Aug 01, 2024 / 12:00PM GMT
Release Date Price: $153.15 (+8.18%)
Operator

Good day, everyone, and welcome to today's Neurocrine Biosciences Reports second quarter results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note, today's call will be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.

Todd Tushla
Neurocrine Biosciences Inc - Investor Relations

Thank you, Chloe. Welcome to Neurocrine Biosciences' second quarter 2024 earnings call. With me are Kevin Gorman, our current Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eiry Roberts, Chief Medical Officer; Eric Benevich, Chief Commercial Officer; and Kyle Gano, Chief Business Development and Strategy Officer, who on October 14 will become Neurocrine's next CEO. So yes, this will be Kevin's last earnings call, and he plans to share a few closing thoughts following Q&A.

Before we begin, we will be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot